FDA Backs Pooling Alzheimer's and Parkinson's Safety Data for Buntanetap NDA
ANVS sits 23% above its 52-week low of $0.616.
Summary
FDA agreed to Annovis's plan to pool safety data from its Alzheimer's and Parkinson's programs into a single Integrated Summary of Safety supporting the buntanetap NDA. The pooled database will span three randomized, placebo-controlled trials plus one open-label extension, with more than 1,600 participants expected to have received the drug by the DUET-AD 6-month readout. This lets the company build the safety package now while DUET-AD and the OLE PD study are still running, rather than waiting for each program to finish. It is a procedural win, not an efficacy result — FDA's agreement does not mean the NDA will be filed, accepted, or approved, and the submission still hinges on DUET-AD efficacy and safety data. The company had $2.8 million of cash at September 30 and a going-concern warning, with the $21.0 million November offering funding operations from here, so the timeline to the DUET-AD readout is the binding constraint.
At the time of this announcement, ANVS was trading at $0.76 on NYSE in the Life Sciences sector, with a market capitalization of approximately $46.4M. The 52-week trading range was $0.62 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.